Get the Stockscreener App
169.12
1.46%
2.44
Irhythm Technologies Inc stock is traded at $169.12, with a volume of 532.03K.
It is up +1.46% in the last 24 hours and up +26.79% over the past month.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
See More
Previous Close:
$166.68
Open:
$167.12
24h Volume:
532.03K
Relative Volume:
1.09
Market Cap:
$5.43B
Revenue:
$560.03M
Net Income/Loss:
$-150.66M
P/E Ratio:
-34.80
EPS:
-4.86
Net Cash Flow:
$-87.43M
1W Performance:
+5.32%
1M Performance:
+26.79%
6M Performance:
+41.59%
1Y Performance:
+142.15%
1-Day Range:
$166.51
$172.59
1-Week Range:
$152.05
$172.59
52-Week Range:
$55.92
$172.59
Irhythm Technologies Inc Stock (IRTC) Company Profile
Name
Irhythm Technologies Inc
Sector
Industry
Phone
415-632-5700
Address
699 8TH STREET, San Francisco, CA
Compare IRTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRTC
Irhythm Technologies Inc
|
169.12 | 5.07B | 560.03M | -150.66M | -87.43M | -4.86 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Irhythm Technologies Inc Stock (IRTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-03-24 | Resumed | Wells Fargo | Equal Weight |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Jun-20-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-11-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Feb-07-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-22 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Apr-06-22 | Initiated | Wolfe Research | Underperform |
| Feb-24-22 | Upgrade | Needham | Hold → Buy |
| Jan-18-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-12-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-11-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-21-21 | Resumed | Canaccord Genuity | Buy |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-02-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Colliers Securities | Buy → Neutral |
| Jan-29-21 | Reiterated | Needham | Hold |
| Nov-17-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-11-20 | Initiated | Needham | Hold |
| Sep-02-20 | Initiated | Robert W. Baird | Neutral |
| Aug-07-20 | Upgrade | Colliers Securities | Neutral → Buy |
| Aug-05-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-10-20 | Initiated | William Blair | Outperform |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Oct-22-19 | Initiated | Oppenheimer | Perform |
| Feb-20-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Sep-13-18 | Reiterated | Canaccord Genuity | Buy |
| Sep-06-18 | Initiated | Chardan Capital Markets | Buy |
| Aug-02-18 | Upgrade | Dougherty & Company | Sell → Neutral |
| Jul-16-18 | Downgrade | Dougherty & Company | Neutral → Sell |
| Dec-01-17 | Initiated | Dougherty & Company | Neutral |
View All
Irhythm Technologies Inc Stock (IRTC) Latest News
iRhythm Technologies to Participate in Upcoming Investor Conferences - The Manila Times
Digital Health Leader iRhythm Technologies Set for Wells Fargo, Morgan Stanley, Baird Conferences - Stock Titan
iRhythm up on Buy coverage at BofA on market expansion opportunities - Seeking Alpha
IRhythm Technologies' Zio MCT to Serve as Catalyst for Market Share Gains, BofA Says - MarketScreener
B of A Securities initiates coverage on iRhythm Technologies with a Buy rating, PT $200. - AInvest
This Figma Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating - MSN
iRhythm Technologies (IRTC) Surpasses Q2 Revenue Forecasts, Raises Outlook - MSN
iRhythm Technologies Exceeds Q2 Revenue Forecasts, Raises Full-Year Outlook - AInvest
AVALON Study Builds on CAMELOT Study Reinforcing iRhythm’s LTCM Clinical Performance - Diagnostic and Interventional Cardiology
iRhythm Technologies falls after Spruce Point issues short-selling report - TradingView
Investor Short Report Flags Steep Downside Risk For iRhythm Technologies - Benzinga
Spruce Point issues strong sell report on iRhythm Technologies - MarketScreener
Spruce Point says it’s short iRhythm, sees 40%-70% potential LT downside - TipRanks
Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on iRhythm Technologies (NASDAQ: IRTC) - Business Wire
AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority - The Manila Times
428,707-Patient Study: iRhythm's Heart Monitor Doubles Diagnosis Rate, Cuts Healthcare Costs by $816/Patient - Stock Titan
AI Tracker: Vendor says AI model gets 100% score on medical exam - Modern Healthcare
iRhythm Technologies Inc. Crosses 200 Day MA — Signal or Noise2025 Technical Patterns & Fast Entry and Exit Trade Plans - sundaytimes.kr
Introducing the CSO finalists in our C-Suite Leaders Awards - The Business Journals
Published on: 2025-08-14 23:53:49 - classian.co.kr
ECG Patch and Holter Monitor Market Set to Witness Significant - openPR.com
Alignment Healthcare, Bio-Techne, Envista, iRhythm, and UFP Technologies Shares Skyrocket, What You Need To Know - Yahoo Finance
Local health-tech startup secures $2.3M to accelerate AI tools, double workforce - The Business Journals
IRTC Q2 Deep Dive: Core Business Momentum and Product Expansion Shape Outlook - Yahoo Finance
Artificial Intelligence in Remote Patient Monitoring Market - openPR.com
Artificial Intelligence in Remote Patient Monitoring Market Poised to Grow at 27.13% CAGR Through 2032, Reports DelveInsight | Medtronic, iRhythm, Philips, Siemens Healthineers, GE HealthCare, etc - Barchart.com
Morgan Stanley Maintains Buy Rating for Irhythm Technologies with $195 Price Target - AInvest
Chad Patterson Sells 2,555 Shares of iRhythm Technologies Inc, Modestly Overvalued According to GF Value - AInvest
Don't Ignore The Insider Selling In iRhythm Technologies - simplywall.st
iRhythm Technologies' Chief Commercial Officer Sells 2,555 Shares - AInvest
iRhythm Fails to Halt Information Exchange in Investor Lawsuit - Bloomberg Law News
Top Executives Cash Out Big on Irhythm Technologies Stock! - TipRanks
Top Executives Cash Out on Irhythm Technologies Stock Amid Strong Earnings and Raised Price Targets. - AInvest
Stewart Won't Reconsider Her 1st Settled Expectations Denial - Law360
Stewart Denies iRhythm’s Bid to Review Decision Scrapping IPRs Based on ‘Settled Expectations’ - IPWatchdog.com
Insider Selling at iRhythm Technologies: Signal or Noise in a High-Flying Stock? - AInvest
Truist Financial Sticks to Their Buy Rating for Irhythm Technologies (IRTC) - The Globe and Mail
Truist Financial Reiterates Buy Rating for Irhythm Technologies with $175 Price Target - AInvest
iRhythm Technologies Sees Boosted Price Target Following Strong Earnings - AInvest
Why Are iRhythm Technologies Shares Dropping? - TipRanks
Is It Too Late To Consider Buying IRhythm Technologies, Inc. (NASDAQ:IRTC)? - 富途牛牛
iRhythm Technologies, Inc. (NASDAQ:IRTC) Just Reported And Analysts Have Been Lifting Their Price Targets - simplywall.st
What is the risk reward ratio of investing in iRhythm Technologies Inc. stockMaximize portfolio growth with strategic plans - Jammu Links News
What analysts say about iRhythm Technologies Inc. stockRapidly growing investment returns - Jammu Links News
How strong is iRhythm Technologies Inc. company’s balance sheetCapitalize on momentum-driven stocks - Jammu Links News
iRhythm’s Strategic Moves and Strong Q2 Performance Boost Stock - StocksToTrade
When is iRhythm Technologies Inc. stock expected to show significant growthUnlock superior stock analysis tools - Jammu Links News
How volatile is iRhythm Technologies Inc. stock compared to the marketTap into rapid wealth building techniques - Jammu Links News
Is iRhythm Technologies Inc. a growth stock or a value stockExponential return rates - Jammu Links News
What catalysts could drive iRhythm Technologies Inc. stock higher in 2025Achieve consistent profits with proven strategies - Jammu Links News
Irhythm Technologies Inc Stock (IRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Irhythm Technologies Inc Stock (IRTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TALWALKAR ABHIJIT Y | Director |
Aug 11 '25 |
Option Exercise |
10.71 |
5,312 |
56,892 |
25,611 |
| TALWALKAR ABHIJIT Y | Director |
Aug 11 '25 |
Sale |
158.02 |
5,312 |
839,381 |
20,299 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):